News

Press Releases

Year

Mar 24, 2020

Tricida Announces Multiple Data Presentations on Veverimer and Metabolic Acidosis to Be Given at the Virtual National Kidney Foundation 2020 Spring Clinical Meetings

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Mar. 24, 2020-- Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of its drug candidate, veverimer (TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in

Mar 12, 2020

Tricida Supports the National Kidney Foundation in Asking “Are You the 33%?”

Take the Kidney Risk Quiz at MinuteForYourKidney.Org SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)-- Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of its drug candidate, veverimer (TRC101), a non-absorbed, orally-administered polymer

Mar 09, 2020

Tricida Hires Robert McKague as Executive Vice President, General Counsel & Chief Compliance Officer

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)-- Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of its drug candidate, veverimer (TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with

Feb 27, 2020

Tricida Announces Fourth Quarter and Full-Year 2019 Financial Results

Webcast Today at 4:30 pm Eastern Time SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)-- Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of its drug candidate, veverimer (TRC101), a non-absorbed, orally-administered polymer designed to treat

Feb 24, 2020

Tricida to Present at the Cowen 40th Annual Health Care Conference

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Feb. 24, 2020-- Tricida, Inc. (Nasdaq: TCDA) today announced that it will present at the Cowen 40 th Annual Health Care Conference on Monday, March 2, 2020 at 11:10 am PT / 2:10 pm ET . Geoff Parker , Tricida’s Chief Financial Officer, will provide a

Feb 19, 2020

Tricida to Report Fourth Quarter and Year End 2019 Financial Results and Host Conference Call and Webcast on Thursday, February 27, 2020

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Feb. 19, 2020-- Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of its drug candidate, veverimer (TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in

Jan 07, 2020

Tricida to Present at the 38th Annual J. P. Morgan Healthcare Conference

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jan. 7, 2020-- Tricida, Inc. (Nasdaq: TCDA) today announced that it will present at the 38 th Annual J. P. Morgan Healthcare Conference on Tuesday, January 14, 2020 at 9:30 am PT / 12:30 pm ET . Gerrit Klaerner , Ph.D., Tricida’s Founder, Chief